VRTX Vertex Pharmaceuticals, Inc.

$VRTX $XBI $IBRX Not a single 💙 on my VRTX Posts. I’m either suppressed here, or have NO fans. Makes me wonder. Few Posters have been more right about VRTX than me. By the way, IBRX is a Vertex in the making. ImmunityBio is unstoppable! Regardless, Grok knows!

$VRTX Vertex Pharmaceuticals reinstated with an Overweight at JPMorgan JPMorgan reinstated coverage of Vertex Pharmaceuticals with an Overweight rating and price target of $560, up from $515, following a period of restriction. Vertex continues to expand with the recent Crinetics acquisition adding exposure to endocrinology, the analyst tells investors in a research note. The firm expects immediate sales contribution from Palsonify, and, in time, atumelnant, to make the deal accretive to operating income by 2029.

$VRTX This analyst didn’t miss the ‘Overton’ window. As in the new FDA Chiefs background in ‘Pain’.

$VRTX why is this beaten to death??? They should do some buybacks. Management has to wake up.

$VRTX Pove and Pain will be the upcoming focus. New data overdue! WS finally catching up.

$VRTX OptionsFLO flow and daily chart read. The alert snapshot shows $436K in the Oct 16 $525 puts. Volume was 17.5x standing open interest at capture. Daily chart through Sep 25: last close $526.19, below its 20 day average and above its 50 day average, with RSI at 53. The 3 month range is $465.00 to $560.25. Intraday volume does not establish whether a position was opened or held; the next settled open interest is the check.

$VRTX JOURNAVX: 535K Q2 scripts → only $50M revenue. WAC ~$15.50/tablet while common generic pain meds cost pennies — yet PBM/Medicare access keeps expanding. PBM-engineered access, not some miracle-demand story. Ask pharmacists how many overpriced “next big thing” drugs get pushed for a year, then vanish into formulary oblivion. Wall Street calls it a blockbuster. Pharmacy has seen this movie before. NEXT STOP $476 🔥